Expert Insights On New Advances In Wound Care
- Volume 16 - Issue 1 - January 2003
- 5546 reads
- 0 comments
As Aristidis Veves, MD and Thanh Dinh, DPM, point out, it is well-known that the chronic diabetic foot ulcer is stuck in the inflammation phase of the wound healing cycle. Research studies have shown that non-healing wounds may have specific biochemical imbalances, notes Liza Ovington, PhD. In particular, non-healing wounds have been shown to have excessively high levels of proteolytic enzymes such as matrix metalloproteases (MMPs).
While these enzymes are necessary in various aspects of the healing process, such as cellular migration, debridement and phagocytosis, Dr. Ovington notes that higher than normal levels of these enzymes contribute to non-healing via uncontrolled degradation of granulation tissue components and local destruction of growth factors.
With these things in mind, our expert panelists discuss what the future may hold for new advances in wound care.
Q: What product/technology do you see on the horizon as the next commercially available adjunct to help heal chronic wounds?
A: Dr. Ovington points to Promogran, a topical dressing composed of collagen and oxidized regenerated cellulose. She says this recent addition to the wound healing armamentarium is designed to reduce local levels of MMPs, a particular family of protein-degrading enzymes.
Oscar M. Alvarez, PhD, notes that a multi-center study proved that Promogran is effective for treating diabetic foot ulcers. He adds that in vitro studies have shown that this dressing modulates MMPs and protects growth factors from digestion. According to Dr. Alvarez, there is evidence in general that cellulose inhibits certain MMPs in chronic wounds, which reduces the proteolytic environment that is “so unfriendly to migrating epithelium.”
In the future, Gerit Mulder, DPM, says he expects to see modifications of current wound dressings that allow them to act as delivery systems for drugs and cell mediators.
ExCell is another wound dressing that can provide moisture to the wound if it is dry and absorb moisture from the wound if it is too moist. Dr. Alvarez says this microbially-derived cellulose dressing provides a good environment for autolytic debridement as well as healing. He adds that clinical studies on venous ulcers are underway.
Pre-clinical research with a nitric oxide releasing hydrogel dressing has been promising, according to Dr. Alvarez, who notes that impaired wound healing in diabetics has been associated with reduced nitric oxide synthesis. Dr. Alvarez also notes that noncontact, normothermic wound therapy with Warm-Up has recently been shown to significantly reduce healing time in diabetic foot ulcers when compared to standard care.
Q: What is the future of topical growth factors?
A: Dr. Mulder says growth factors are considered appropriate adjunctive treatment for difficult wounds when standard approaches have failed. Researchers have shown that using becaplermin gel augments chronic wound healing via the addition of recombinant platelet-derived growth factor (PDGF), according to Drs. Dinh and Veves. They also note that bioengineered tissue, such as Apligraf and Dermagraft, has been successful in treating chronic diabetic foot ulcers. Drs. Dinh and Veves say these bioengineered tissues introduce metabolically active fibroblasts and keratinocytes that facilitate the expression of growth factors and cytokines into the chronic wound.
Dr. Mulder believes tissue substitutes will evolve into biological materials, which will remain viable for longer periods of time, be more complex in structure and have broader indications than currently available products.
With the introduction of Promogran, which reduces MMPs, Dr. Ovington says “we may see improved results from existing topical growth factor therapies such as Regranex (becaplermin) and bioengineered tissues.”